# An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis

> **NCT07013110** · PHASE2 · RECRUITING · sponsor: **Prof Salvatore Albani** · enrollment: 124 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA)
- Rheumatology

## Interventions

- **DRUG:** dnaJP1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07013110
- **Lead sponsor:** Prof Salvatore Albani
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-18
- **Primary completion:** 2028-11
- **Final completion:** 2028-11
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2025-08-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07013110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07013110, "An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07013110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*